Breast carcinoma, mammary carcinoma, malignant breast tumor, breast malignancy, carcinoma of the breast Breast cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Age = 70 yearsHistologically confirmed invasive breast cancerClinical stage cT1N0M0 based on mammography and ultrasoundER-positive, HER2-negative (IHC 0-1+ or 2+ with negative ISH), any PR statusPresence of concurrent DCIS is allowed if limited to <25% of the pre-NST biopsy, with no radiologic suspicion of an extensive componentUnifocal disease <2 cm, well visualized on ultrasound, with a minimum distance of =5 mm from the skin, nipple and thoracic wallAbility and willingness to comply with project requirementsPreoperative endocrine therapy is allowedWritten informed consent given by the subject
Exclusion criteria
Exclusion criteria: Pure DCIS lesions without invasive componentExtensive calcifications on imaging suggestive of widespread diseaseInvasive lobular carcinoma (as assessed by IHC)Triple-negative or HER2-positive subtype (defined as (IHC 3+ or ISH positive)History of ipsilateral breast cancer or DCISPrior ipsilateral radiotherapyInability to communicate in Dutch or English languagePlanned (e)migration or long-term stay abroad within one year after inclusion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measure is the safety and feasibility of cryoablation in this patient population. This will be assessed by:incidence and type of adverse events and complications up to 3 months post-procedure, classified according to CTCAE v5.0;technical success and procedural feasibility (complete treatment of the tumor, procedure performed as planned).Secondary outcomes include recovery, cosmetic outcomes, quality of life, and patient satisfaction. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes include recovery, cosmetic outcomes, quality of life, and patient satisfaction. | — |
Countries
Netherlands
Contacts
Antonius Ziekenhuis